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Objective: This study aims to investigate the regulation of expression of Cartilage oligomeric matrix protein
(COMP), which is predominately expressed by chondrocytes and functions to organize the extracellular
matrix. Mutations in COMP cause two skeletal dysplasias: pseudoachondroplasia and multiple epiphyseal
dysplasia. The mechanism controlling COMP expression during chondrocyte differentiation is still poorly
understood.
Design: Primary human bone marrow-derived stem cells were induced to differentiate into chondrocyte
by pellet cultures. We then compared the temporal expression of COMP with the well-characterized
cartilage-speciﬁc Type II collagen (Col2a1), and their response to transforming growth factor (TGF)
b and Sox trio (Sox5, 6, and 9) stimulation.
Results: COMP and Col2a1 expression are differentially regulated by three distinct mechanisms. First,
upregulation of COMP mRNA precedes Col2a1 by several days during chondrogenesis. Second, COMP
expression is independent of high cell density but requires TGF-b1. Induction of COMPmRNA by TGF-b1 is
detected within 2 h in the absence of protein synthesis and is blocked by speciﬁc inhibitors of the TGFb
signaling pathway; and therefore, COMP is a primary TFGb-response gene. Lastly, while Col2a1 expression
is intimately controlled by the Sox trio, overexpression of Sox trio fails to activate the COMP promoter.
Conclusion: COMP and Col2a1 expression are regulated differently during chondrogenesis. COMP is
a primary response gene of TGFb and its fast induction during chondrogenesis suggests that COMP is
suitable for rapidly accessing the chondrogenic potential of stem cells.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The cartilage oligomeric matrix protein (COMP), also known as
thrombospondin (TSP)-5, is a member of the TSP family that modu-
lates numerous biological functions involving the organization of the
extracellular matrix1. COMP is a pentameric non-collagenous matrix
protein expressed predominantly by chondrocytes2,3. Some muta-
tions in the human COMP gene cause retention of misfolded COMP
within the endoplasmic reticulum, leading topremature chondrocyte
death and bone growth retardation; these clinically present as two
skeletal dysplasias (pseudoachondroplasia and multiple epiphyseal
dysplasia)4,5.
The pentameric COMP is proposed to function as a linker protein
between collagen and other extracellular matrix molecules thato: J.H.N. Yik, Department of
loskeletal Research Center,
4635 Second Ave, Research
ax: 1-916-734-5750.
s Research Society International. Pregulate collagen ﬁbrilogenesis6e9. COMP knock-out mice are
phenotypically normal10, suggesting that COMP’s functionmight be
compensated by other members of the TSP family or other extra-
cellular matrix constituents. In support of this, single deletion
models of COMP and collagen IX do not result in disruption of
epiphyseal growth plate architecture as seen in the double deletion
mouse model11. Moreover, compound nulls involving TSP-1, -3,
COMP, and collagen IX result in drastic changes in growth plate
organization and reduction in length of the limbs not seen in single
deletion models12. Collectively, these in vivo studies demonstrate
a role of COMP in organizing the growth plate architecture.
It is not entirely clear what factors contribute to the cartilage-
speciﬁc expression pattern of COMP. Posey et al. show that the ﬁrst
375 nucleotides of the human COMP promoter contains cis-
regulatory element that is sufﬁcient to drive cartilage-speciﬁc
expression of a reporter gene in mice13. However, the signaling
pathways and transcription factors that can directly activate the
expression of COMP gene are still poorly understood. The expression
of COMP in articular chondrocytes is stimulatedbyTFG-b, implicating
the involvement of the transforming growth factor (TGF)ublished by Elsevier Ltd. All rights reserved.
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is upregulated in cells subjected to mechanical stimuli16.
COMP expression changes rapidly during chondrocyte differen-
tiation and dedifferentiation when compared to the widely used
chondrocytic marker collagen type II (Col2a1)17, indicating the
potential use of COMP as an early marker for accessing the chon-
drogenic potential. In addition, the differences in the temporal
expression of COMP and Col2a1 suggest that they are regulated
differently during cartilage development. Since current knowledge
of regulation of COMP expression relies heavily on established cell
lines, we performed a detailed comparative analysis between COMP
and Col2a1 temporal expression patterns during in vitro stimulation
of chondrocyte differentiation from primary human bone marrow-
derived stem cells (BMSC). We also compared COMP and Col2a1’s
response to regulation by the TGF-b1 signaling pathway as well as
the chondrocyte-speciﬁc transcription factors L-Sox5, Sox6, and
sex-determining region Y-box 9 (Sox9).
Methods
Cell culture
Human bone marrow aspirates from the femur of 10 patients
undergoing total knee arthroplasty were obtained after IRB approval.
Primary BMSC were isolated according to a previously described
protocol18 and maintained in MSCGM media (PT-3001 from Lonza),
supplemented with 1 ng/ml basic ﬁbroblastic growth factor (Roche).
The BMSC was characterized by ﬂow cytometry to conﬁrm the
presence of characteristic mesenchymal stem cell surface antigens
(CD73, CD90, CD105) and the absence of hematopoietic stem cell
(CD14, CD34) and monocyte markers (CD45) (data not shown). The
pluripotency of BMSC was conﬁrmed by their in vitro differentiation
into: chondrogenic lineage as indicatedbypositive Col2a1 expression
and Alcian blue staining; osteogenic lineage as indicated by calcium
mineralization; and adipogenic lineage as indicated by neutral
lipid19. BMSC between passages 2 and 6 were used for the experi-
ments throughout this study (at least two different donors per
experiment). The immortalized human chondrocyte cell line C20/A4
(a generous gift from Dr. Mary Goldring at Harvard University) was
maintained in DMEM (high glucose) supplemented with 10% fetal
bovine serum and 1% penicillinestreptomycin (all from Invitrogen).
Plasmids
Human L-Sox5 (clone ID 9204249), Sox6 (9203962) and Sox9
(9205725) cDNA clones were purchased (Openbiosystem) and
subcloned into pFLAG-CMV2 expression vector (Invitrogen) using
standard PCR techniques. The human 3Kb COMP promoter
(nucleotides 3026 to þ22) and 0.37Kb COMP promoter (375
to þ22) were cloned from genomic DNA into pGL4.10 luciferase
vector (Invitrogen) with or without the addition of the 48-bp Sox9-
binding sequence20 immediately downstream of the transcription
start site. The luciferase reporter plasmid containing 12 48-bp
Sox9-binding site21 was a kind gift from Dr. Hiroshi Asahara, The
Scripps Research Institute, La Jolla, CA.
Generation of lentivirus
Human Sox6 and Sox9 cDNA were subcloned into the pCCL-
based lentiviral vector and packaged in 293T cells as
described22. BMSC were infected at ﬁve multiplicity of infection
with 1 mg/ml polybrene. Lentivirus generated from the empty
pCCL plasmid were used as control. Media was replaced 16 h later
and the cells were harvested 2 days after infection for mRNA
analysis.Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA from cells grown as monolayer or pellet culture in the
presenceorabsenceof 10 ng/ml TGF-b1 (Peprotech) for various times
were extracted using an RNeasy Mini Kit with DNase I (both from
Qiagen) and then reverse transcribed with poly-dT primers using
a Superscript ﬁrst-strand kit (Invitrogen). Quantitative real-time PCR
was performed as triplicate measurements using the TaqMan Gene
Expression Assay and ABI Prism 7700 Sequence Detection System
according to manufacturer’s instructions (Applied Biosystems)
using the following primers: COL2A1 Hs01064869_m1, L-Sox5
Hs00374709_m1, Sox6 Hs00264525_m1, Sox9 Hs00165814_m1,
COMPHs00164359_m1. The level of each target genewasnormalized
to GAPDH and expressed as fold-change relative to the levels at time
0 (Ct method; Applied Biosystems).
Luciferase assay
C20/A4 cells were seeded in 24-well plates at 70% conﬂuence
and cultured overnight. 5 ng of a Renilla Luciferase reporter
(pTK-RL from Promega), together with the Sox trio plasmids (2 ng
each) were co-transfected in triplicates with the 3Kb/0.37Kb COMP
or 3Kb/0.37Kb COMPþ 48 bp luciferase reporter constructs (50 ng),
using Lipofectamine and Plus Reagent according to the manufac-
turer’s instructions (Invitrogen). Empty vectors were used to adjust
the DNA content to a total of 0.4 mg in all transfections. After 48 h
post-transfection, cells werewashedwith PBS and lysed in 100 ml of
luciferase lysis buffer (Promega).10 ml of cell lysatewere assayed for
luciferase activity using the Dual Luciferase Assay System
(Promega) with the Glomax 20/20 luminometer (Promega). Fireﬂy
luciferase activities were normalized to the corresponding Renilla
luciferase activities to adjust for differences in transfection/
expression efﬁciency. The value determined from the control for
each construct (without Sox trio co-transfection) was set to 100%.
Western blot analysis
BMSC treated with 10 ng/ml TGF-b1 for various times were har-
vestedand lysedwithsample loadingbuffer (50 mMTriseHCl, pH6.8;
100 mM dithiothreitol; 4% 2-mercaptoethanol; 2% sodium dodecyl
sulfate; 10% glycerol). Lysates were resolved by 8% SDS-
polyacrylamide gels, transferred onto nitrocellulose membranes
(Whatman), and subjected to Western blot analysis. The membranes
were blockedwith 2% BSA in TBST (25mM TriseHCl, pH 7.5; 125 mM
NaCl; 0.1% Tween 20), followed by incubation with rabbit polyclonal
antiserum speciﬁc for human COMP23, Col2a1 (Santa Cruz Biotech-
nology) and mouse anti-GAPDH (Ambion) at 4C overnight. Blots
were thenprobedwithhorseradishperoxidase-conjugated secondary
antibody (Santa CruzBiotechnology), and reactive proteinbandswere
visualized with Western Lightning Plus-ECL (Perkin Elmer).
In vitro chondrogenesis
5105 BMSC were pelleted in 15 ml polypropylene tubes by
centrifugation (500g, 5 min) and cultured in 5% CO2 incubator at
37C for 1e2 weeks in BMSC Chondrogenic SingleQuots medium
(Lonza) supplementedwith 10 ng/ml TGF-b1 (R&D Systems). Media
was changed every 3e4 days.
Statistical analysis
Results are presented as the mean, 95% conﬁdence interval (CI),
and standard deviation. Paired Student’s t-tests were used for
statistical analysis.
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Induction of COMP begins at an early phase of chondrogenesis
Previous studies suggested that the changes in COMP expres-
sion, during differentiation and dedifferentiation of chondrocytes
occur more rapidly when compared to other widely used cartilage
markers, such as Col2a117. To determine whether COMP could be
used as an early and sensitive marker for chondrogenesis of
primary human BMSC, we compared the temporal expression of
COMP and Col2a1, during a 14-day time course of BMSC chondro-
genesis induced by high-density pellet culture and TGF-b1. Quan-
titative real-time PCR revealed that at day 3 of chondrogenesis, the
level of COMP mRNA increased w7-fold and continued to elevate
throughout the entire time course [Fig. 1(A), left panel]. In contrast,
the expression of Col2a1 remained undetectable at day 3 and could
only be detected at day 7 or later [Fig. 1(A), right panel]. The protein
expression of COMP and Col2a1 correlated with their mRNA levels,
but only in the presence of TGF-b1 [Fig. 1(B)], indicating induction
of COMP and Col2a1 expression in pellet culture is largely TGF-b1-
driven. These results demonstrate a delay in the expression of
Col2a1 relative to COMP, and hence suggest that the expression of
these two genes might be subjected to different regulators during
the initial phase of chondrogenesis.Fig. 1. Induction of COMP expression precedes that of Col2a1. (A) COMP mRNA is
expressed before Col2a1 during chondrogenesis of BMSC pellet culture. Total RNA was
isolated from primary human BMSC cultured as high-density pellet in chondrogenic
media containing TGF-b1 for 3, 7, or 14 days. The mRNA expression levels of the COMP
and Col2a1 were measured using quantitative RT-PCR and normalized to GAPDH. The
values shown for each gene at a given time points were fold-induction relative to un-
induced BMSC at day 0 (mean with 95% CI, n¼ 3). A CT value of >40 PCR cycle was
deemed undetectable. *Student’s t-test comparing day 0 to day 3 (P¼ 0.0425), day 7
(P¼ 0.004), and day 14 (P< 0.0001). (B) COMP protein is detected earlier than Col2a1
during chondrogenesis. Human primary BMSC grown in pellet culture were treated
with or without TGF-b1 for the indicated time points. The amounts of COMP and
Col2a1 proteins recovered from cells and their associated extracellular matrix were
detected by Western blot.TGF-b1 stimulates early expression of COMP mRNA independent of
high cell density
Since TGF-b1 and high cell density are two well known factors
that drive stem cell chondrogenesis, we next determined whether
both TGF-b1 and high cell density are required for the induction of
COMP expression. BMSC cultured asmonolayer tow70% conﬂuence
in basal media were treated with 10 ng/ml TGF-b1; then at various
time points the expression of COMP and Col2a1 mRNA was deter-
mined. The data showed that expression of COMP mRNA in mono-
layer BMSC culture was induced by TGF-b1 within 2 h and
continued to increase for the entire 2-week-time course [Fig. 2(A),
left panel]. The magnitude of COMP’s induction was markedly
higher in monolayer culture when compared to pellet culture. This
can be seen by comparing thew7-fold induction of COMP at day 3
pellet culture [Fig. 1(A), left panel], and the w57-fold induction of
COMPat day 3monolayer culture [Fig. 2(A), left panel]. These results
indicate that TGF-b1 stimulates COMP expression in BMSC inde-
pendent of high cell density. In fact, high cell density appears to be
inhibitory to TGF-b1-mediated induction of COMP. In contrast to
COMP, Col2a1 expression in monolayer culture in the presence of
TGF-b1 remained undetectable at earlier time points (2 h to 3 days)
and was only elevated w5-fold at 2 weeks [Fig. 2(A), right panel],
compared to more than 300-fold induction in pellet culture atFig. 2. TGF-b1 stimulates COMP expression independent of high cell density. (A) Induction
of COMP mRNA precedes that of Col2a1 in monolayer BMSC. Primary human BMSC
grown as monolayer culture to w70% conﬂuence was treated with TGF-b1 for the
indicated time points. The mRNA levels of COMP and Col2a1 were measured as
described above (mean with 95% CI, n¼ 3). P-values from Student’s t-test comparing
COMP mRNA at time 0 to: 2 h (P¼ 0.0639), 4 h (P¼ 0.0051), 8 h (P¼ 0.0069), day 1
(P¼ 0.0213), day 3 (P¼ 0.0004), and day 14 (P¼ 0.0062). (B) TGF-b1 stimulates
synthesis of COMP protein. Human primary BMSC grown in monolayer were treated
with TGF-b1 for the indicated time points. The amounts of COMP protein recovered
from cells and their associated extracellular matrix were detected by Western blot
using a rabbit polyclonal anti-COMP antibody.
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cell density and three-dimensional culturing condition is required
for robust expression of Col2a1.
Upregulation of COMP protein by TGF-b1
Given the induction of COMP mRNA occurred within hours of
TGF-b1 treatment, we next determinedwhether the protein level of
COMP is also elevated. BMSC from two different donors grown in
monolayer were treated with TGF-b1 for the indicated times. Cells
and their associated extracellular matrix were collected and the
amounts of COMP protein were determined by Western blot. The
results showed that induction of COMP protein could be detected as
early as 8 h and was markedly increased at 72 h [Fig. 2(B)], thus
correlated well with the mRNA expression patterns. Note that the
increase in COMP protein is strictly dependent on TGF-b1 as no
COMP can be detected at 72 h in the absence of TGF-b1.
COMP is directly activated by the TGF-b signaling pathway
In order to determine if the TGF-b1-mediated signaling pathway
is responsible for the upregulation of COMP expression in BMSC, we
pre-treated BMSC in monolayer culture with the speciﬁc TGF type I
receptor kinase inhibitor SB-43154224, followed by stimulationwithFig. 3. COMP is an early response gene regulated by TGF-b1. (A) TGF-b1 signaling pathway is
treated with the indicated amount of the speciﬁc TGF receptor type I inhibitor SB-431542
measured as described in Fig. 1(A). (B) BMSC grown in monolayer were pre-treated with th
24 h. The mRNA level of COMP was measured as described in Fig. 1(A). (C) Induction of COM
were pre-treated with 20 mM Chx for 2 h, followed by the addition of TGF-b1 for 24 h. The m
95% CIs, n¼ 3). (D) Parallel BMSC samples from C were lysed in sample buffer and the leveTGF-b1 for 24 h. The results demonstrated that SB-431542 signiﬁ-
cantly inhibited TGF-b1-induced COMP expression at a concentra-
tion of 10 mM, but not at 1 mM [Fig. 3(A)]. Next, we tested the ability
of another pharmacological inhibitor, SIS3 (speciﬁc inhibitor of
Smad3)25, to suppress the basal and TGF-b1-induced transcription
of COMP. The results showed that while the basal transcription of
COMP was not affected, the TGF-b1-mediated activation of COMP
was suppressed by SIS3 in a dose-dependent manner [Fig. 3(B)].
Taken together, these data demonstrate the direct involvement of
TGF-b signaling pathway in activating COMP mRNA expression in
BMSC.COMP is an early response gene targeted by TGF-b
Given the fast response (within 2 h) of COMP induction by TGF-b1,
we next asked whether COMP is induced directly by TGF-b1 or if
additional protein synthesis is required to produce secondary factors
that in turn stimulate COMP expression. Monolayer BMSC culture
was pre-treated with the protein synthesis inhibitor cycloheximide
(Chx), followed by stimulation with TGF-b1. The results showed that
despite the presence of Chx, TGF-b1 was still able to stimulate COMP
mRNA expression to the same extent as the untreated control
[Fig. 3(C)]. The effectiveness of Chx treatment was conﬁrmed by
Western analysis,which showednonewly synthesizedCOMPproteininvolved in the induction of COMP expression. BMSC grown in monolayer were pre-
for 2 h, followed by stimulation with TGF-b1 for 24 h. The mRNA level of COMP was
e indicated amount of SIS3 for 2 h, followed by treatment with or without TGF-b1 for
P mRNA by TGF-b1 does not involve new protein synthesis. BMSC grown in monolayer
RNA level of COMP was measured as described above (all data shownwere means with
l of COMP protein was determined by Western blot analysis.
Fig. 4. COMPpromoter-driven luciferase constructs used for Sox trio activation study. The
12 48 bp construct is a luciferase reporter plasmid containing 12 copies of the 48-bp
Sox9-binding sequence (from the ﬁrst intron of Col2a1 gene) cloned next to a basal
promoter. The 3Kb COMPþ 48 bp and 0.37Kb COMPþ 48 bp construct were obtained by
inserting a single copy of the 48-bp Sox9-binding site immediately downstream to the
transcription start site of the respective COMP promoter constructs.
Table II
Activation of different COMP promoter-driven luciferase constructs by Sox trio
(n¼ 3)
Construct Sox9 Sox5 Sox6 Relative luciferase unit
(Mean fold of control, 95% CI)
P-value
12 48 bp
   100.0 (85.1e111.4) e
þ   1,808.2 (1,666.8e1,907.4) 0.0018
3Kb COMP
   100.1 (96.5e104.5) e
þ   62.5 (59.3e64.6) 0.0010
 þ  115.0 (113.6e116.6) 0.0147
  þ 132.1 (122.0e142.5) 0.0298
þ þ  114.9 (97.9e141.1) 0.3096
þ  þ 67.0 (62.6e70.1) 0.0098
þ þ þ 158.7 (138.2e177.1) 0.0229
3Kb COMPþ 48 bp
   101.4 (88.0e111.5) e
þ   173.1 (146.8e188.2) 0.0503
 þ  137.3 (115.7e149.6) 0.0190
  þ 296.5 (274.5e330.1) 0.0037
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that additional protein synthesis is not required for TGF-b1-mediated
stimulation of COMP expression. Hence, COMP can be classiﬁed as
a primary response gene of the TGF-b signaling pathway.
Expression of Sox trio remains unchanged in BMSC after 24 h
TGF-b1 treatment
Both COMP and Col2a1 are predominately expressed in chon-
drocytes. As noted above, the induction of COMP mRNA by TGF-b1
occurred days before the expression of Col2a1 was detected, sug-
gesting that although expressed in the same cell types, the tran-
scription of these two genes might be activated by different
mechanisms or transcription factors. It is well documented that
Col2a1 expression is activated by the coordinated action of the
transcription factors Sox9, L-Sox5, and Sox6 (the so called Sox
trio)26,27. In contrast, conﬂicting data exist regarding whether Sox9
can activate COMP expression13,28,29. Therefore, we sought to deter-
mine whether TGF-b1-mediated induction of COMP in primary
humanBMSC corresponds to a concomitant elevation in the Sox trio’s
expression. The changes in mRNA expression of the Sox trio in the
presenceof TGF-b1within24 hweredetermined. The results showed
that TGF-b1 markedly stimulated COMP expression as before,
however, the mRNA levels of Sox9, Sox5, and Sox6 did not change
signiﬁcantly (<2-fold), and the expression of Col2a1 remained
undetectable (Table I). These data suggest that the upregulation of
COMP by TGF-b1 is not due to an increase in Sox trio expression.
The human 3Kb COMP promoter is not activated by Sox trio
The core human COMP promoter (þ1 to 375 nt) can direct
cartilage-speciﬁc expression of a reporter gene inmouse13, and a 3Kb
region upstream to the core promoter contains chondrocyte-speciﬁc
enhancer elements13 (and our unpublished data). Previously, a puta-
tive 13-bp Sox9-binding site was identiﬁed in the mouse COMP
promoter29, and this sequence, located at 80 nt upstream of the
transcription start site, is also conserved in the human COMP
promoter. To further conﬁrm whether Sox trio activates the human
COMP promoter, we performed luciferase reporter assays using
constructs driven by various promoters (Fig. 4); these include
a positive control (12 48 bp) with a basal promoter linked to 12
copies of a 48-bp Sox9-binding element in the ﬁrst intron of the
Col2a1 gene21, the human COMP promoter (3Kb COMP) encom-
passing a 3Kb region upstream of the transcription start site
(nucleotide 3026 to þ22), and the human 3Kb COMP promoter
linked to a single copy of the 48-bp Sox9-binding site (3Kb
COMPþ 48 bp). As shown in Table II, co-transfection with Sox9-
expressing plasmid markedly activated the Sox9-responsive
promoter (12x48 bp) in C20/A4 cells as expected; however, Sox9
alone or in combination with Sox5 or Sox6 failed to activate the
human 3Kb COMP promoter, indicating the absence of a Sox9-
responsive element within this 3Kb region. In contrast, insertion of
a 48-bp Sox9-binding element into the human COMP promoter
immediately upstream of the transcription start site allowed theTable I
Changes in mRNA levels of Sox 5, 6, 9 and COMP after 24 h TGF-b1 treatment (n¼ 3)
Untreated TGF-b1-treated P-value
Mean fold-change in mRNA (95% CI)
Sox5 1.08 (0.65e1.62) 0.29 (0.12e0.49) 0.1794
Sox6 1.12 (0.59e1.84) 1.08 (0.83e1.55) 0.9538
Sox9 1.19 (0.59e2.22) 1.81 (1.53e2.02) 0.2688
COMP 1.14 (0.67e2.01) 10.54 (8.40e13.18) 0.0251
Col2a1 Undetectable Undetectable eCOMP promoter to be markedly activated by Sox9 and Sox5/6 co-
transfection. These data suggest that a Sox9-binding site is absent
in the 3Kb human COMP promoter. The 3Kb COMP promoter
construct contains extra upstream sequence in addition to the 375 bp
core promoter. To rule out the possibility of this extra region acting as
a repressor for Sox trio activation of the core promoter, luciferase
constructs driven by only the core 0.37Kb COMP promoter with or
without insertion of the 48 bp Sox9-binding sequence were gener-
ated (see Fig. 4). These constructs were then tested for Sox trio acti-
vation. The results showed that similar to the 3Kb COMP, the core
0.37Kb COMP promoter alone cannot be activated by Sox trio
(Table II). Whereas the addition of the 48 bp Sox-binding sequence
again allowed the 0.37Kb core promoter to be activated by Sox trio.þ þ  1,522.5 (1,370.3e1,630.8) 0.0033
þ  þ 760.4 (718.9e793.7) 0.0012
þ þ þ 2,331.7 (2,091.2e2,600.6) 0.0047
0.37Kb COMP
   99.8 (97.8e101.1) e
þ   73.4 (71.2e74.9) 0.0046
þ þ þ 152.6 (149.1e156.9) 0.0028
0.37Kb COMPþ 48 bp
   100.2 (98.4e102.5) e
þ   134.6 (121.0e147.6) 0.0506
þ þ þ 758.1 (729.7e802.2) 0.0010
Table III
Differential activation of endogenous COMP and Col2a1 mRNA expression by Sox
trio (n¼ 3)
Mean folds of control (95% CI)
COMP P-value Col2a1 P-value
C20/A4
Control 1.01 (0.87e1.19) e 1.00 (0.99e1.01) e
Sox9 0.76 (0.62e1.03) 0.3696 1.23 (1.19e1.26) 0.0065
Sox5 & 6 1.64 (1.29e2.11) 0.0521 1.25 (1.19e1.30) 0.0129
Sox5, 6, & 9 0.67 (0.44e0.81) 0.0625 95.27 (85.63e114.56) 0.0103
BMSC
Control 1.00 (0.91e1.06) e 1.00 (0.95e1.06) e
Sox9 1.15 (1.05e1.25) 0.0168 28.73 (20.95e36.02) 0.0236
Sox6 1.30 (1.27e1.35) 0.0149 14.14 (11.21e16.19) 0.0123
Sox6 & 9 1.59 (1.39e1.80) 0.0468 7,169 (6,293e7,856) 0.0041
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start site does not act as a repressor for Sox trio activation.
Ectopic expression of Sox trio activates endogenous Col2a1,
but not COMP expression
The above results did not rule out the presence of a Sox trio-
responsive element outside of the 3Kb COMP promoter; and there-
fore, we next tested whether ectopic expression of Sox9 alone or
with Sox5/6 could activate the endogenous human COMP promoter.
Plasmids encoding Sox5, 6, & 9 (100 ng each) were transfected into
the immortalized human chondrocyte cell line C20/A4 grown in
6-well plates in triplicates, and the expression of endogenous COMP
and Col2a1 mRNAs were determined by quantitative RT-PCR. The
results showed that the Sox trio together induced w100-fold tran-
scription of the endogenous Col2a1mRNAs in C20/A4 cells (Table III).
On the other hand, neither Sox9 alone, nor in combinationwith Sox5
and 6, could signiﬁcantly activate endogenous COMP mRNA
expression in C20/A4 (Table III). Next, Sox6 and Sox9 were ectopi-
cally expressed in primary BMSC by lentiviral transduction and the
results again showed that only endogenous Col2a1, but not COMP
mRNA was activated by Sox6 and/or Sox9 (Table III). The fact that
only endogenous Col2a1, but not COMP expression, in an established
chondrocyte cell line and in primary BMSC is successfully activated
by Sox trio strongly implicates that COMP is not subjected to the Sox
trio regulation.
Discussion
Our current knowledge on the regulation of COMP expression
relies heavily on data from established cell lines. In this study we
examined the temporal expression of COMP, with respect to the
most widely used chondrocytic marker Col2a1, during chondro-
genesis of primary human BMSC. Our data clearly demonstrated
that COMP expression during chondrogenesis precedes that of
Col2a1, and this may indicate a role of COMP in early chondro-
genesis. In support of this, Kipnes et al. demonstrate that over-
expression of COMP enhances chondrogenesis of mesenchymal
stem cells30.
The expression of COMP mRNA is speciﬁcally and rapidly
induced (within 2 h) by TGF-b1 in the absence of new protein
synthesis. Therefore, COMP can be classiﬁed as a primary TGF-b-
response gene. Given that TGF-b is commonly used in cartilage
engineering and repair to stimulate chondrogenesis of stem cells,
COMP could proved be a valuable early marker for rapidly
accessing the chondrogenic potential of stem cells; this is in sharp
contrast to the common marker Col2a1, which is usually detect-
able only after several days of chondrogenesis in a pellet culture
system.Although both COMP and Col2a1 are predominantly expressed
by chondrocytes, these two proteins differ in their temporal
expression during chondrogenesis. In addition, we also show that
COMP and Col2a1 differ in their responses to regulation by the Sox
trio. It is well established that Col2a1 is activated by the coordi-
nated action of the Sox trio. In contrast, despites several potential
Sox9-binding sites being identiﬁed in human and mouse COMP
promoters29,31, contradictory data exist regarding whether Sox trio
directly regulates COMP expression. Two independent studies
show that overexpression of Sox9 failed to activate either the
human COMP promoter in mouse 3T3 ﬁbroblast13, or the mouse
COMP promoter in rat chondrosarcoma and mouse C3H10T1/2
mesenchyme cell lines31. In contrast, Liu et al. demonstrated that
Sox9 alone activates the mouse COMP promoter in rat chon-
drosarcoma cell line, and L-Sox5/Sox6 work synergistically on this
activation29.
The discrepancy in the above studies might arise from the
different promoter expression systems and cell lines/species being
employed in these studies. Whereas in the present study, our data
clearly demonstrate the inability of Sox9 alone or with L-Sox5 and
Sox6 to activate the COMP promoter-driven luciferase construct, as
well as the endogenous human COMP promoter. Furthermore, using
primary human BMSC, we show that endogenous COMP mRNA is
rapidly induced by TGF-b1 treatment while at the same time, Col2a1
expression is undetectable and the Sox trio expression remains
unchanged. Collectively, these data point to the same conclusion and
strongly suggest that TGF-b1-mediated induction of COMP is inde-
pendent of the Sox trio regulation. Since two of the three analyzed
observations were provided by the same donor, and the statistical
evaluation of the results is based on an assumption of three different
donors, the uncertainty of the results is greater than indicated by
their P-values. However, the fact that COMP expression has also been
reported in cell types other than chondrocytes such as skin ﬁbro-
blasts32 and vascular smooth muscle cells33, in which Sox9 expres-
sion is not detected, strongly argues against the involvement of Sox9
in COMP expression.
Interestingly, TSP-1, a close relative of COMP within the TSP
protein family, is also an early response gene of the TGF-b signaling
pathway34. However, in addition to the inductionof itsmRNAby TGF-
b1, the TSP-1 protein can also speciﬁcally bind to the latent form of
TGF-b1 and mediate its activation in endothelial cells, which in turn
regulates cell adhesion and migration that are important in post-
natal development of epithelial structure and during wound heal-
ing34,35. Therefore, the induction of TSP-1 by TGF-b1 appears to form
a positive feed-back loop to augment TGF-b signaling in endothelial
cells. However, the TGF-b1-binding domain (Type I repeat domain) in
TSP-1 is not present in COMP; and therefore, whether other domains
of COMP can directly or indirectly interact with TGF-b1 remains to be
determined.
In summary, we have characterized COMP as a primary response
geneof the TGF-b signalingpathwayandprovide new insight into the
regulation of COMP expression during chondrogenesis of human
BMSC. These results suggest that COMP might be a suitable early
marker for rapidly accessing the chondrogenic potential of stemcells.
The possibility of manipulating the expression of COMP through
controlling the TGF-b pathway might also lead to novel therapeutic
intervention in the management of pseudoachondroplasia and
multiple epiphyseal dysplasia.
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